Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 моноклональный антитело, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective антитело-dependent клетка-mediated cytotoxicity (ADCC).
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.